Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02292225 · ClinicalTrials.gov registry record · Phase 1
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
A Phase 1 study, sponsored by SecuraBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02292225 is a Phase 1 study that was terminated before completion, run by SecuraBio. The registered enrollment target is 3 participants.
The verdict
NCT02292225, a Phase 1 study, was terminated before completion, sponsored by SecuraBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
To evaluate the safety, pharmacokinetics, and pharmacodynamics of Duvelisib (IPI-145) in combination with obinutuzumab in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi.
Interventions
- DRUG Obinutuzumab
- DRUG IPI-145 (duvelisib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02292225
The ClinicalTrials.gov registry entry for NCT02292225 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT02292225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02292225 about?
NCT02292225 is a clinical study titled "Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)". To evaluate the safety, pharmacokinetics, and pharmacodynamics of Duvelisib (IPI-145) in combination with obinutuzumab in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi.
What is the current status of trial NCT02292225?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2015-02. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02292225?
The interventions under investigation include: Obinutuzumab (DRUG), IPI-145 (duvelisib) (DRUG).
Who is sponsoring clinical trial NCT02292225?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.